This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.
The committee also recommended that Faslodex could be used in combination with Pfizer ’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative ... The combination can also be used
The US FDA has approved the CDK 4/6 inhibitor - which will be sold as Verzenio - as a combination treatment with hormone drug fulvestrant for hormone receptor-positive, human epidermal growth
US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone deficiency drug somavaratan failed a phase III trial. ... The long-acting human growth hormone (hGH) product had been billed as a successor to
New chief executive David Ricks needs the drug and other growth brands to fire on all cylinders to help Lilly ride through the recent disappointment of a surprise FDA rejection for ... receptor-positive (HR+), human epidermal growth factor receptor
The US FDA has converted its earlier conditional approval of Ibrance (palbociclib) into full approval as a first-line treatment of post-menopausal women with hormone receptor positive, human epidermal growth
menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
More from news
Approximately 1 fully matching, plus 19 partially matching documents found.
Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Palbociclib is approved for the treatment of patients with locally advanced or metastatic breast cancer, specifically those who have hormone receptor-positive and human epidermal growth factor receptor 2-negative disease. ... The committee found that
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...